Skip to main content
TipRanks
Go Ultimate75% OFF

Black Diamond Therapeutics (BDTX) AI Stock Analysis

1,666 Followers
BDTX

Black Diamond Therapeutics

(NASDAQ:BDTX)

Select Model
Rating:44Neutral
Price Target:$1.50â–²(2.04% Upside)
Action:reiterated
Date:11/11/26

The score is weighed down primarily by inconsistent financial performance and ongoing TTM losses/cash burn despite a stronger low-debt balance sheet, alongside weak technical signals with the price below major moving averages and negative MACD. Valuation is also challenged by a negative P/E and no dividend yield data to offset risk.

Positive Factors
Conservative Balance SheetLow leverage and positive equity provide a financial cushion while the company funds clinical development. This reduces balance-sheet pressure relative to a highly indebted biotech and preserves flexibility to allocate capital toward trials, regulatory work, and pipeline advancement.
Negative Factors
Current Cash BurnNegative trailing cash flow means the company is consuming resources rather than funding development internally. If this pattern persists, available cash will decline and management may need additional financing, which could constrain clinical execution or dilute existing shareholders.

Black Diamond Therapeutics (BDTX) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%BDTX-62.97%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$84.48M
Dividend Yield
―
Average Volume (3M)
703.96K
Price to Earnings (P/E)
-1.9
Beta (1Y)
2.08
Revenue Growth
-100.00%
EPS Growth
-302.37%
Country
US
Employees
21
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Black Diamond Therapeutics Business Overview & Revenue Model

Company Description

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDT...

How the Company Makes Money

BDTX is a clinical-stage biotechnology company and, as such, it generally does not generate recurring commercial product revenue unless it has an approved product (null). Its funding and revenue sources typically come from (i) collaboration and licen...

Black Diamond Therapeutics Financial Statement Overview

Summary

Balance sheet is a relative strength with low leverage and positive equity (TTM equity ~$88.1M; debt-to-equity ~0.18). However, operating results and cash flows are unstable: profitability in 2025 (net income $22.4M; positive FCF $29.6M) contrasts with the most recent TTM net loss (-$44.1M) and negative free cash flow (-$33.3M), indicating uncertain revenue durability and ongoing burn.

Income Statement

28Negative

Balance Sheet

62Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue070.00M0000
Gross Profit-55.00K69.67M0-437.00K00
EBITDA-44.59M22.69M-69.33M-82.00M-90.66M-125.39M
Net Income-44.07M22.37M-69.68M-82.44M-91.17M-125.60M
Balance Sheet
Total Assets115.56M143.01M122.64M158.57M156.25M247.68M
Cash, Cash Equivalents and Short-Term Investments102.03M128.65M98.58M131.40M122.81M209.79M
Total Debt16.04M18.78M22.19M25.30M28.14M28.46M
Total Liabilities27.48M30.80M39.35M41.83M40.56M51.78M
Stockholders Equity88.08M112.21M83.28M116.74M115.69M195.90M
Cash Flow
Free Cash Flow-32.50M29.61M-62.30M-66.75M-85.27M-102.86M
Operating Cash Flow-32.50M29.61M-62.30M-66.72M-85.08M-100.15M
Investing Cash Flow17.70M-44.91M16.97M16.35M53.37M130.61M
Financing Cash Flow-152.00K-146.00K25.55M71.93M177.00K729.00K

Black Diamond Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price1.47

Price Trends

50DMA1.85Negative
100DMA1.90Negative
200DMA2.15Negative

Market Momentum

MACD-0.08Positive
RSI37.06Neutral
STOCH4.68Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Negative. The current price of 1.47 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.85, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 4.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDTX.

Black Diamond Therapeutics Risk Analysis

Black Diamond Therapeutics disclosed 81 risk factors in its most recent earnings report. Black Diamond Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Black Diamond Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BDTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ONCYONCY46Neutral$47.18M-1.32664.95%――11.90%
BDTXBDTX44Neutral$84.48M-1.93-43.99%―-100.00%-302.37%
ADCTADCT43Neutral$188.49M-2.5636.95%―12.85%63.71%
KZIAKZIA42Neutral$75.65M-0.94-116.86%―-98.25%76.83%
TCRXTCRX38Underperform$10.89M-0.18-140.75%―-38.43%20.89%

* Healthcare Sector Average

Performance Comparison

0%100%BDTXKZIAONCYADCTTCRXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BDTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BDTXBlack Diamond Therapeutics, Inc.1.47-2.54-63.34%
KZIAKazia Therapeutics Limited6.620.548.88%
ONCYOncolytics Biotech0.37-0.68-64.76%
ADCTADC Therapeutics Ltd1.34-2.63-66.25%
TCRXTscan Therapeutics, Inc.0.16-0.81-83.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026